Primary aldosteronism is the most common cause of secondary hypertension. The two main types of primary aldosteronism are aldosteronoma(30%) and adrenal hyperplasia(60%). The gold standard that determines the diagnosis and treatment strategy of primary aldosteronism is adrenal vein sampling(AVS), but the success rate is only about 80%. Using CXCR4 as a probe for 68Ga-Pentixafor PET/CT imaging can guide the classification diagnosis and treatment strategy of primary aldosteronism, which is a favorable supplement to AVS. Superselective adrenal artery embolization(SAAE) and laparoscopy are the main operation treatments for primary aldosteronism. SAAE is an invasive interventional operation. It is a novel way to evaluate the changes in the structure and function of adrenal tissue pre-postoperative SAAE by using the changes in 68Ga-Pentixafor PET/CT imaging.
adult population (aged 18 years or order);
patients with suspected or new diagnosed Primary aldosteronism (supporting evidence may include MRI, CT, laboratory tests);
patients who had scheduled 68Ga-BNU-PSMA PET/CT scan;
patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee;
patients with pregnancy;
the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Single group
68Ga-Pentixafor
Diagnostic testEach patient receive a single intravenous injection of 68Ga-Pentixafor, and undergo PET/CT scan within specified time.
Standardized uptake value (SUV)
Standardized uptake value (SUV) of 68Ga-Pentixafor for each target or suspected lesion of subject.
SAAE treatment evaluation
68Ga-Pentixafor PET/CT imaging to evaluate the changes in the structure and function of adrenal tissue pre-postoperative SAAE.
Click on the lead sponsor to view all of their trials.
